Clinical trials: Postmenopausal Disorder
- Condition Postmenopausal Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Osteoporosis
Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
This study will evaluate clinical safety and pharmacokinetics of Maxmarvil® in healthy postmenopausal women
- Trial name
- YY_PK_2011 (NCT01526278)
- Testing
- Maxmarvil®
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yuyu Pharma, Inc.
Osteoporosis
A Phase I Study of AK159 in Healthy Postmenopausal Women
The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.
- Trial name
- NCT01935479
- Testing
- AK159, MN-10-T
- Where
- 3 sites in Japan
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Asahi Kasei Therapeutics Corporation
Relative Bioavailability
A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations
This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women.
- Trial name
- NCT04686669
- Testing
- FOR-6219 capsule formulation, FOR-6219 tablet formulation
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Forendo Pharma Ltd
Osteoporosis
A Study of SB751689 in Japanese Postmenopausal Women
To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.
- Trial name
- NCT00554255
- Testing
- SB751689
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
- Trial name
- NCT01011725
- Testing
- MK 0773
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteopenia
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese…
- Trial name
- NCT01101061
- Testing
- Romosozumab
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Amgen
Osteoarthritis
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly other bone disorders. Recent results suggest that relacatib interacts with the way our bodies metabolise drugs and so some drugs which…
- Trial name
- NCT00411190
- Testing
- Relacatib, Acetaminophen, Ibuprofen
- Where
- 2 sites in Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Postmenopausal Bone Loss
Effects of Arzoxifene on Bone Mass and the Uterus
The purposes of this study are to determine: The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. The effects of arzoxifene on the uterus (womb) in postmenopausal women.
- Trial name
- NCT00085956
- Testing
- Arzoxifene
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Osteopenia
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
- Trial name
- NCT00902356
- Testing
- AMG 167
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Osteopenia, Osteoporosis
Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women
The primary objective of this clinical trial is to determine the effects of hesperidin on biochemical markers of bone in post-menopausal women.
- Trial name
- NCT00545116
- Testing
- Hesperidin
- Where
- Malaysia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Muscular Atrophy
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
The purpose of this study is to establish safe dose levels of ACE-031 in healthy postmenopausal women following multiple dose administration. This study will also evaluate if ACE-031 has an effect on muscle.
- Trial name
- NCT00952887
- Testing
- ACE-031
- Where
- 2 sites in Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Healthy Volunteers
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
This study will be a fixed sequence drug-drug interaction study in healthy postmenopausal females, conducted at multiple study sites
- Trial name
- NCT05438303
- Testing
- AZD9833, Midazolam, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Osteoporosis, Postmenopausal
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
This is an observational study to investigate the prevalence of osteoporotic fractures in post menopausal patients. Post menopausal patients who visit OS(orthopedic surgery) including GHs(general hospitals) and clinics will be…
- Trial name
- TOP (NCT01381588)
- Testing
- Fracture evaluation
- Where
- South Korea
- Volunteers
- 1,136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).
- Trial name
- NCT00769418
- Testing
- odanacatib
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women
The primary objectives of the study are to assess the safety and tolerability of AGA2118 after single subcutaneous or intravenous administration in healthy men and postmenopausal women and to assess the safety and tolerability of…
- Trial name
- NCT05225857
- Testing
- AGA2118
- Where
- 2 sites in Australia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Angitia Biopharmaceuticals
Muscle Loss
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
Single center, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of ACE-031 in healthy postmenopausal volunteers
- Trial name
- NCT00755638
- Testing
- ACE-031
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Epilepsy
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-sodium valproate (VPA) .
- Trial name
- NCT03681158
- Testing
- sodium valproate
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Sanofi